A NOVEL ROLE OF SGLT2 INHIBITORS TO INCREASE CIRCULATING PROANGIOGENIC PROGENITOR CELLS IN PATIENTS WITH TYPE 2 DIABETES AND ESTABLISHED CARDIOVASCULAR DISEASE: A SUB-STUDY OF THE EMPA-HEART CARDIOLINK-6 TRIAL